Patent classifications
A61K47/551
Compositions and Methods for the Delivery of Therapeutics
The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.
Vitamin E-Nucleoside Prodrugs
The present disclosure describes nucleoside and nucleoside analogues that are conjugated to a vitamin E derivative via a phosphate ester or a phosphoramidate linkage. The nucleoside or nucleoside analogues can provide enhanced therapeutic activity (e.g., antiproliferative activity against tumor cells) and/or greater chemical stability in aqueous solutions.
Anxiety Treatment Kit
This present invention relates to an anxiety treatment kit for an individual to help reduce anxiety and panic in the individual. The anxiety treatment kit includes a plurality of anxiety coping items from which a user can choose to remain calm and grounded. The anxiety coping items include, but are not limited to, rubber bands, lavender oil, sour powder, CBD products, cold and squishy items, inspirational cards and meditation or relaxation tips to relax and calm a user during the time of an anxiety attack. The anxiety treatment kit may be made available both as a one-time purchase or in a subscription-based model. The box of the present invention is reusable, and features an easy open lid to provide convenient access to the anxiety coping items stored therein.
CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS
Cytotoxic lymphocytes expressing chimeric antigen receptors (CAR) that target and bind small conjugate molecules (SCM) are disclosed, as well as methods of using the cells and the SCMs in the treatment of cancer.
METHODS OF TREATING CANCER WITH TUBULYSIN CONJUGATES
The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.
SYNTHESIS OF NANOCOMPOUNDS COMPRISING ANATASE-PHASE TITANIUM OXIDE AND COMPOSITIONS CONTAINING SAME FOR THE TREATMENT OF CANCER
This invention relates to novel nanocompounds that are cytotoxic to tumor cells when combined with ultraviolet light, the nanocompounds comprising multilayered carbon nanotubes with anatase-phase titanium dioxide or anatase-phase titanium dioxide and folate. The invention also relates to a composition containing said nanocompounds and to a method for the treatment of cancer; comprising the administration of said composition in co-treatment with UV radiation. The invention further relates to a method for the synthesis of the nano-compounds.
STEALTH, TARGETED NANOPARTICLES (STN) FOR ORAL DRUG DELIVERY
The present invention relates to a technology for oral delivery of Poorly Bio-Available Therapeutic Agents and the formulations derived using this technology. Poorly Bio-Available Therapeutic Agents may belong to BCS class III/IV drugs or nutraceutical or any other agent which is required to be orally delivered having challenge of bio-availability in body. Therefore, invention further relates to a targeted delivery technology for enhanced bio-availability and controlled release without being degraded. The present invention further relates to the processes for the preparation of said compositions and formulations made thereof. The formulations of the present invention are useful to treat related conditions.
TFPI inhibitors and methods of use
The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
Prodrugs activated by caspase
Described are prodrug conjugates that release a chemotherapeutic agent upon activation by caspase, and methods using such prodrug conjugates to induce apoptosis, amplify apoptosis, and treat cancer.
Transgenic plants expressing cobalamin binding proteins
The present invention relates to the use of transgenic plants for the expression of vitamin B12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin B12 binding proteins. The present invention also relates to the use of recombinant vitamin B12 binding proteins from plants in analytical tests and treatment of vitamin B12 deficiency. Also disclosed is a method for purification of recombinant vitamin B12 binding proteins.